Bakiah Shaharuddin et al., STEM CELLS Translational Medicine
Limbal stem cell deficiency is a painful eye condition caused by abnormal maintenance of limbal stem cells. It is treated by transplantation of limbal epithelial cells derived from human tissue. The success of this treatment depends of the quality of the cells transplanted; however, some transplants fail. Understanding more about the immunobiology of these cells within the transplants could improve the outcomes. However, the human tissue needed as a supply of stem cells for this research is not readily available. As an alternative, a human telomerase-immortalized corneal epithelial cell line may be used. This study shows that this cell line contains limbal stem cells. Moreover, these cells have characteristics and immunobiological functions similar to those of tissue-derived limbal cells. These results suggest that this cell line is a useful model for improving the understanding of limbal stem cell biology.
Enrico Ragni et al., STEM CELLS
Mesenchymal stem cells (MSC) are on the edge of innovation aimed at future therapeutic applications, and many pathways explaining MSC potential have been discovered and dissected. This work demonstrates that secreted vesicles may shuttle therapeutic messenger RNA to recipient cells to educate them in order to reduce inflammation and cell death. Such new evidence adds a new player to the existing knowledge aimed at the definition of MSC potential.
Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger’s Disease: Phase II Study Report Suggests Clinical Efficacy
Pawan K. Gupta et al., STEM CELLS Translational Medicine
Critical limb ischemia (CLI) due to Buerger’s disease presents a major unmet medical need. The limited therapeutic options lead to increased morbidity and mortality. This study showed that use of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells is safe and efficacious when the cells are injected intramuscularly at a dose of 2 million cells/kg body weight in patients with CLI. Rest pain and ulcer healing significantly improved in most patients. This regimen may be a novel therapeutic option for Buerger’s disease.
Charles S Cox Jr. et al., STEM CELLS
This phase I/IIa study of adult severe traumatic brain injury (TBI) sought to confirm the safety and logistic feasibility of autologous bone marrow mononuclear cells, as well as determine a potential treatment effect size of white matter structural preservation. The study found that the fractional anisotropy (FA) and mean diffusivity (MD) in the corticospinal tract are clearly improved by bone marrow mononuclear cell treatment, and the improvement in FA in the corpus callosum has a treatment effect significant enough to calculate power for a future phase II study. View the Video Highlight here.
Video abstract from Dr. Cooke, et al. on his recently published STEM CELLS paper entitled, "Retinoic Acid Inducible Gene 1 Protein (RIG1)-like Receptor Pathway is Required for Efficient Nuclear Reprogramming." Read the paper here.
Video abstract from Drs. Cox, Hetz, Liao, Aertker, Ewing-Cobbs, Juranek, Savitz, Jackson, Romanowska-Pawliczek, Triolo, Dash, Pedroza, Lee, Worth, Aisiku, Choi, Holcomb, and Kitagawa on their recently published STEM CELLS paper entitled, "Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells." Read the paper here.Video Library